BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27158668)

  • 1. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
    Minson KA; Smith CC; DeRyckere D; Libbrecht C; Lee-Sherick AB; Huey MG; Lasater EA; Kirkpatrick GD; Stashko MA; Zhang W; Jordan CT; Kireev D; Wang X; Frye SV; Earp HS; Shah NP; Graham DK
    JCI Insight; 2016 Mar; 1(3):e85630. PubMed ID: 27158668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
    Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
    Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
    Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
    Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
    Yamatani K; Ai T; Saito K; Suzuki K; Hori A; Kinjo S; Ikeo K; Ruvolo V; Zhang W; Mak PY; Kaczkowski B; Harada H; Katayama K; Sugimoto Y; Myslinski J; Hato T; Miida T; Konopleva M; Hayashizaki Y; Carter BZ; Tabe Y; Andreeff M
    Transl Oncol; 2022 Apr; 18():101354. PubMed ID: 35114569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.
    Xiao X; Wang P; Zhang W; Wang J; Cai M; Jiang H; Wu Y; Shan H
    Cancer Cell Int; 2023 Nov; 23(1):302. PubMed ID: 38037057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
    Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
    Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
    Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 15. Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia.
    Zhang Y; Wang P; Wang Y; Shen Y
    Biomark Res; 2023 Jan; 11(1):8. PubMed ID: 36691065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.
    Wang X; DeFilippis RA; Weldemichael T; Gunaganti N; Tran P; Leung YK; Shah NP; Li HY
    Eur J Med Chem; 2024 Jan; 264():115977. PubMed ID: 38056299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
    Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
    Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
    Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
    Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
    Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.